Rigel Pharmaceuticals Files 2024 Annual Report
Ticker: RIGL · Form: 10-K · Filed: Mar 4, 2025 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 10-K |
| Filed Date | Mar 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Rigel Pharma dropped its 2024 10-K. Check financials.
AI Summary
Rigel Pharmaceuticals Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, headquartered in South San Francisco, CA, operates in the pharmaceutical preparations industry. Key financial data and operational details for the period are presented in this comprehensive filing.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Rigel Pharmaceuticals' financial health, operational performance, and strategic outlook for the past fiscal year.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Rigel faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.
Key Numbers
- 17,710,216 — Total Assets (Reported for the fiscal year ending December 31, 2024.)
- 17,482,513 — Total Liabilities (Reported for the fiscal year ending December 31, 2024.)
Key Players & Entities
- RIGEL PHARMACEUTICALS INC (company) — Filer
- 611 GATEWAY BOULEVARD, SUITE 900 (address) — Business and Mail Address
- SOUTH SAN FRANCISCO, CA 94080 (address) — Business and Mail City, State, Zip
- 650-624-1100 (phone) — Business Phone
- 2024-12-31 (date) — Fiscal Year End
FAQ
What were Rigel Pharmaceuticals' total revenues for the fiscal year ended December 31, 2024?
The provided text does not explicitly state total revenues for the fiscal year ended December 31, 2024. It lists financial statement line items such as Sales Returns and Allowances, Government and Other Rebates, and Chargebacks, Discounts and Fees for 2024 and 2023.
What is Rigel Pharmaceuticals' primary business activity?
Rigel Pharmaceuticals Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When was this 10-K filing submitted to the SEC?
This 10-K filing was filed as of March 4, 2025.
What is the company's state of incorporation?
Rigel Pharmaceuticals Inc. is incorporated in Delaware (DE).
What are the reported total assets and total liabilities for the fiscal year ending December 31, 2024?
For the fiscal year ending December 31, 2024, Rigel Pharmaceuticals reported total assets of $17,710,216 and total liabilities of $17,482,513.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 4, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).